Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

n Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy of SNS-595, SNS-032 and SNS-314, planned additional clinical testing and development efforts, the timing of enrollment in clinical trials and the announcement of clinical results. Words such as "look forward," "suggests," "may," "expects," "designed," "believe," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for SNS-595, SNS-032 and/or SNS-314 may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials and manufacturing of SNS-595, SNS-032 and SNS-314 and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' annual report on Form 10-K for the year ended December 31, 2006 and other filings with the Securities and Exchange Commission.
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... CO (PRWEB) August 27, 2014 Flagship ... analysis services to the pharmaceutical and medical device ... expansion. The fast growing company has consolidated its ... Aurora and Boulder to Westminster, CO, just north of ... Histology Lab, 7575 W. 103rd Ave., Suite 100, Westminster, ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014 is ... of the global isotope ratio mass spectrometer industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, a ... technologies, today announced that it has been selected as ... Industry Association,s 2014 Awards for Excellence competition ... an independent panel of judges from SCORE (Counselors to ... winners will be honored at a gala event to ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... 7 ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading ... cells, announced today that it will be,participating in the ... 10, 2008., The Company,s presentation by Dr. William ... Standard Time (11:50 am, Pacific Standard,Time), and will be ...
... cubes and spheres move aside. Tiny gold stars, smaller ... for new approaches to medical diagnoses or testing for environmental ... wide spectrum of sciences, a new study by Duke University ... stars may shine above all the rest for certain applications. ...
... Upon a Proven Class of Drugs With Greater Tumor ... (Nasdaq: ONXX ) today announced that it has,in-licensed ... Limited based in the United Kingdom. Under the terms ... BGC 945 and all of its,related patents. Onyx will ...
Cached Biology Technology:ThermoGenesis Presentation at Rodman & Renshaw Conference 2Gold nanostar shape of the future 2Gold nanostar shape of the future 3Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 2Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 3
(Date:8/26/2014)... St. Louis have developed algorithms to identify weak spots ... breaking. The technology, which needs to be refined before ... pinpoint minor strains and tiny injuries in the body,s ... is available online Aug. 27 in the Journal ... at the nexus of the physical and life sciences. ...
(Date:8/26/2014)... of Warwick have provided the first evidence that ... linked to early signs of dementia. , Published ... that the absence of the protein MK2/3 promotes ... nervous system. These changes were shown to have ... including restricted learning and memory formation capabilities. , ...
(Date:8/26/2014)... In recent years, increasing pressure from policymakers, consumers, ... targets that go beyond reducing the pollutants they ... and lakes. Today companies must also assess environmental ... the mining of primary materials to the use ... has given rise to the discipline known as ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2Yale journal explores advances in sustainable manufacturing 2
... 2011 -- Research presented today at the 31st Annual meeting ... Meeting has found that three proteins known as XIAP, BID, ... progesterone treatments in the prevention of preterm labor. They ... The proteins prevent preterm birth by hindering ...
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... the 4th Congress of the International Society for Hemodialysis ... "The Treatment of HCV with Affinity Plasmapheresis." The conference ...
... today at the 31st Annual meeting of the Society for ... three proteins known as XIAP, BID, and Bcl-2 are responsible ... prevention of preterm labor. They may also play an ... proteins prevent preterm birth by hindering apoptosis the normal, ...
Cached Biology News:New research helps explain how progesterone prevents preterm birth 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 3Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 4Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 5New research helps explain how progesterone preventspreterm birth 2
... The new D-LUX Detection Platform combines ... provide the most sensitive, specific, and ... Invitrogens D-LUX Detection Platform offers exceptional ... to TaqMan probes, high signal/background ratio, ...
...
Request Info...
... Blood is aseptically collected via cardiac puncture ... Zealand White, mixed sex). It is then centrifuged ... pooled, sterile filtered and bottled at 4C then ... IF YOU HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU ...
Biology Products: